{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:28:19Z","timestamp":1767688099854,"version":"3.48.0"},"reference-count":8,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Innovent Biologics, Inc","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety, tolerability and preliminary efficacy of IBI324, a vascular endothelial growth factor-A\/angiopoietin-2 bispecific antibody, in participants with diabetic macular oedema (DME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicentre, open-label, phase 1 dose-escalation clinical trial consisted of a single ascending dose (SAD) stage and a multiple ascending dose (MAD) stage. 24 participants with fovea-involving DME were enrolled. SAD participants received a single intravitreal injection (IVT) of 0.5\u2009mg, 2\u2009mg or 4\u2009mg IBI324 and were followed up until Day 42 post injection. In the MAD stage, six participants each received 3 monthly IVTs of 2\u2009mg or 4\u2009mg IBI324 and were followed up until determined as \u2018treatment needed\u2019 per prespecified criteria or until 24 weeks after first dose. The primary endpoints were incidence of dose-limiting toxicities (DLTs), adverse events (AEs) and changes in vital signs and laboratory test findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No DLT, treatment-related AE, AE of special interest or ocular serious AE was reported. Treatment-emergent adverse events (TEAEs), all mild or moderate in severity, were observed in 4 (33.3%) SAD participants and 11 (91.7%) MAD participants. TEAEs of the study eye included intraocular pressure increased, conjunctival haemorrhage, allergic conjunctivitis, posterior capsular opacification and visual acuity decreased. Mean best-corrected visual acuity increase and mean central subfield thickness decrease from baseline in the study eye were observed in all dose groups, accompanied by intraretinal fluid\/subretinal fluid improvements. 16 weeks after the last dose, 7 (58.3%) MAD 2\u2009mg and 6 (50.0%) MAD 4\u2009mg participants remained free of \u2018treatment needed\u2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IBI324 was well tolerated with evidence of functional and anatomical improvement in patients with DME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05489718\">NCT05489718<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2024-002035","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:25:16Z","timestamp":1767687916000},"page":"e002035","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1 dose-escalation study of IBI324, a VEGF-A\/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct05489718","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05489718","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zilin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"National Clinical Research Center for Ophthalmic Diseases, Shanghai, China"},{"name":"Shanghai Key Laboratory of Fundus Diseases, Shanghai, China"},{"name":"Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-5223","authenticated-orcid":false,"given":"Junran","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"National Clinical Research Center for Ophthalmic Diseases, Shanghai, China"},{"name":"Shanghai Key Laboratory of Fundus Diseases, Shanghai, China"},{"name":"Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0115-7160","authenticated-orcid":false,"given":"Kun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"National Clinical Research Center for Ophthalmic Diseases, Shanghai, China"},{"name":"Shanghai Key Laboratory of Fundus Diseases, Shanghai, China"},{"name":"Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-136X","authenticated-orcid":false,"given":"Qinghuai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jiangsu Province Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaoqin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Zhejiang Provincial People\u2019s Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujie","family":"Lu","sequence":"additional","affiliation":[{"name":"Innovent Biologics Suzhou Co Ltd, Suzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Deng","sequence":"additional","affiliation":[{"name":"Innovent Biologics Suzhou Co Ltd, Suzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Innovent Biologics Suzhou Co Ltd, Suzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[{"name":"Innovent Biologics Suzhou Co Ltd, Suzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-2797","authenticated-orcid":false,"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-0945","authenticated-orcid":false,"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"National Clinical Research Center for Ophthalmic Diseases, Shanghai, China"},{"name":"Shanghai Key Laboratory of Fundus Diseases, Shanghai, China"},{"name":"Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026010600250964000_11.1.e002035.1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4093\/dmj.2018.0182","article-title":"Pathophysiology of Diabetic Retinopathy: The Old and the New","volume":"42","author":"Kusuhara","year":"2018","journal-title":"Diabetes Metab J"},{"key":"2026010600250964000_11.1.e002035.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034"},{"key":"2026010600250964000_11.1.e002035.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.006"},{"key":"2026010600250964000_11.1.e002035.4","doi-asserted-by":"publisher","DOI":"10.1159\/000458539"},{"key":"2026010600250964000_11.1.e002035.5","first-page":"825","article-title":"Faricimab: First Approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026010600250964000_11.1.e002035.6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"2026010600250964000_11.1.e002035.7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"The Lancet"},{"key":"2026010600250964000_11.1.e002035.8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2024-002035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:25:18Z","timestamp":1767687918000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2024-002035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjophth-2024-002035"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2024-002035","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}